How well can in vitro data predict in vivo effects of chemicals? Rodent carcinogenicity as a case study  by Anthony (Tony) Cox, Louis et al.
lable at ScienceDirect
Regulatory Toxicology and Pharmacology 77 (2016) 54e64Contents lists avaiRegulatory Toxicology and Pharmacology
journal homepage: www.elsevier .com/locate/yrtphHow well can in vitro data predict in vivo effects of chemicals? Rodent
carcinogenicity as a case study
Louis Anthony (Tony) Cox a, Douglas A. Popken a, A. Michael Kaplan b,
Laura M. Plunkett c, *, Richard A. Becker d
a Cox Associates, 503 Franklin St., Denver, CO, 80218, USA
b A. Michael Kaplan & Associates, LLC, 23 Wilkinson Drive, Landenberg, PA, 19350, USA
c Integrative Biostrategies LLC, 1127 Eldridge Parkway, Suite 300-335, Houston, TX, 77077, USA
d American Chemistry Council, 700 Second Street NE, Washington, D.C. 20002, USAa r t i c l e i n f o
Article history:
Received 21 October 2015
Received in revised form
3 February 2016
Accepted 7 February 2016




High throughput screening* Corresponding author.
E-mail addresses: tcoxdenver@aol.com (L. Antho
comcast.net (A.M. Kaplan), lmplunkett@inbiostrat.
Becker@americanchemistry.com (R.A. Becker).
http://dx.doi.org/10.1016/j.yrtph.2016.02.005
0273-2300/© 2016 The Authors. Published by Elseviera b s t r a c t
A recent research article by the National Center for Computational Toxicology (NCCT) (Kleinstreuer et al.,
2013), indicated that high throughput screening (HTS) data from assays linked to hallmarks and pre-
sumed pathways of carcinogenesis could be used to predict classiﬁcation of pesticides as either (a)
possible, probable or likely rodent carcinogens; or (b) not likely carcinogens or evidence of non-
carcinogenicity. Using independently developed software to validate the computational results, we
replicated the majority of the results reported. We also found that the prediction model correlating
cancer pathway bioactivity scores with in vivo carcinogenic effects in rodents was not robust. A change of
classiﬁcation of a single chemical in the test set was capable of changing the overall study conclusion
about the statistical signiﬁcance of the correlation. Furthermore, in the subset of pesticide compounds
used in model validation, the accuracy of prediction was no better than chance for about three quarters of
the chemicals (those with fewer than 7 positive outcomes in HTS assays representing the 11 histo-
pathological endpoints used in model development), suggesting that the prediction model was not
adequate to predict cancer hazard for most of these chemicals. Although the utility of the model for
humans is also unclear because a number of the rodent responses modeled (e.g., mouse liver tumors, rat
thyroid tumors, rat testicular tumors, etc.) are not considered biologically relevant to human responses,
the data examined imply the need for further research with HTS assays and improved models, which
might help to predict classiﬁcations of in vivo carcinogenic responses in rodents for the pesticide
considered, and thus reduce the need for testing in laboratory animals.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over the past half century, an enduring intellectual and tech-
nical challenge for risk analysts, statisticians, toxicologists, and
experts in artiﬁcial intelligence, machine-learning and bioinfor-
matics has been to accurately and reliably predict in vivo biological
responses to realistic exposures from in vitro and chemical struc-
ture data. The common goal of many applied research efforts has
been to devise and validate algorithms that give trustworthy pre-
dictions of whether, and by how much, realistic exposures tony (Tony) Cox), amkaplan1@
com (L.M. Plunkett), Rick_
Inc. This is an open access article uchemicals change probabilities of adverse health responses. This
paper examines recent, promising results suggesting that high-
throughput screening (HTS) assay data can be used to predict
in vivo classiﬁcations of rodent carcinogenicity for certain pesti-
cides, and undertakes an independent reanalysis of the underlying
data to determine how well this encouraging claim can be repli-
cated and supported when the same data are analyzed using
slightly different methods.
A goal of regulatory authorities and scientists involved in
chemical risk assessment is to transition to improved approaches
for testing and assessment that reduce the use of animals, are cost
effective, ethical and provide robust information to support risk
assessment and risk management decisions. HTS assay develop-
ment and derivation of prediction models has been a focus of ef-
forts by researchers and regulatory scientists. In principle, every
student of statistics or bioinformatics with access to relevant data isnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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predictive models. All that is required is to deﬁne one or more
dependent variables indicating in vivo responses to chemical ex-
posures in one or more test species of interest (e.g., rodents); to link
data on these responses for a database of chemicals to results of one
or more in vitro assays (e.g., for genotoxicity, gene mutations, or
chromosomal damage in bacteria and in mammalian cell cultures)
and/or chemical structure features, to be used as predictors; and
then to apply one's favorite predictive analytic techniques to see
how well they can predict in vivo responses from the selected
predictors. Investigators with an interest in systems biology may
use possible causal pathways and mechanisms or modes of action
to guide or rationalize their selection of predictors. Others may
prefer pure black-box statistical methods that simply seek the most
predictive patterns, whether or not they conform to any biological
theory or model. Over the decades, many predictive analytics
techniques have been tried, from clustering and regression
modeling, to expert systems (largely in the 1970s to 1990s), to
artiﬁcial neural networks, to current machine-learning methods
such as Random Forest, ensembles of Bayesian Networks, or sup-
port vector machines. For any predictive technique, important
questions regarding training and test set design, model validation,
sensitivity and speciﬁcity of the predictions, and generalizability of
results arise. Yet, the intrinsic interest and importance of the topic,
and the comparative ease of addressing it by applying predictive
analytics software, has generated a large body of literature, replete
with comparisons among methods for various training and test
data sets.
Despite these many efforts, the results of decades of predictive
modeling remain, at best, mixed. For example, in the 1990s, several
quantitative structure-activity relationship (QSAR) computer pro-
grams were developed to screen inventories of chemicals for
mutagenicity and carcinogenicity. Some of the most commonly
used systems which include Deductive Estimation of Risk from
Existing Knowledge (DEREK), Toxicity Prediction by Computer-
Assisted Technology (TOPKAT), and Multiple Computer Auto-
mated Structure Evaluation (MCASE), were promoted as being
valuable for predicting these endpoints (e.g., Patlewicz et al. 2003),
and were used by regulators and by companies to screen and pri-
oritize chemicals for risk assessment. EPA continues to develop,
endorse, and apply such models, claiming that they have
“demonstrated reasonable predictive abilities” (EPA, 2011). How-
ever, when they were applied to a set of chemicals of great practical
interest ea panel of 394 marketed pharmaceuticalse all turned out
to have less than 52% sensitivity for predicting positive Ames as-
says, and even worse accuracy for predicting other genotoxic assay
results (Snyder et al. 2004): “20% of the 124 non-carcinogens were
positive in at least one genotoxicity assaywhile two-thirds of the 77
rodent carcinogens lacked activity in the genotoxicity tests
employed”.
Similarly, even the most successful systems had only about
60%e65% accuracy in an experiment that tested how well the best
predictive algorithms could predict rodent carcinogenicity for 30
chemicals (Benigni and Zito, 2004). Valerio et al. (2007) reported
97% sensitivity but only 53% speciﬁcity for software used by the
Food and Drug Administration (FDA) to predict rodent carcinoge-
nicity of naturally occurring molecules found in human diets (i.e.,
few false negatives but many false positives), while later work by
these authors (Valerio et al. 2010)found that two such software
programs “both exhibited poor performance in predicting [rodent]
carcinogens” when evaluated in an external validation study of 43
phytochemicals. Walmsley and Billinton (2011) noted that even the
reported high sensitivity of some current in vitro test batteries for
predicting rodent carcinogenicity is less encouraging than it seems,
in so far as the same test batteries also misclassiﬁed as many as 9out of 10 non-carcinogens as being carcinogens. In other words, the
predictive power of the in vitro test batteries is not much better
than would be achieved by simply assuming that all chemicals are
rodent carcinogens, thus creating excellent sensitivity (no false
negatives) but poor speciﬁcity (many false positives). The authors
noted that many pharmaceutical compounds now classiﬁed as
probable carcinogens based on genotoxicity results in bacterial and
mammalian cells may not be carcinogens at all.
Finally, a problem long recognized in the scientiﬁc literature is
that a system that could accurately predict rodent carcinogenicity
might have little value for predicting human carcinogenicity. For
example, some have argued that EPA estimates far more chemicals
as being carcinogenic in humans than do other authorities, such as
the International Agency for Research on Cancer (IARC), due largely
to over-reliance on animal data and to the limitation that “the true
predictivity for human carcinogenicity of animal data is even
poorer than is indicated by EPA ﬁgures alone” (Knight et al. 2006).
Differences across species in gross anatomy (e.g., no Harderian,
Zymbal, or preputial glands in humans), pharmacokinetics and
pharmacodynamics, and species-speciﬁc modes of action (e.g.,
alpha 2-microglobulinprotein drop nephropathy in male rat kid-
neys) all contribute to the uncertain relevance of rodent cancer data
to assessing the potential for human carcinogenicity. This paper
focuses on the narrower question of how well rodent carcinoge-
nicity can be predicted from in vitro assay data and chemical
structure (QSAR) information.
In light of this history of limited predictive performance of
available methods, an analysis of the 2013 method of (Kleinstreuer
et al., 2013) was designed around three questions. The ﬁrst question
posed is: How good (i.e., how predictively accurate) are current
rodent carcinogen prediction systems? For example, what are the
rates of false positives and false negatives in external validation test
sets? The second question posed is: Are there fundamental limi-
tations on the ability of computer algorithms to predict accurately
(with high sensitivity and speciﬁcity) the carcinogenicity in rodents
of a broad range of chemicals? For example, are there limits on the
kinds of concepts or patterns that a computer algorithm can learn
from data, and is there reason to believe that a concept such as “is a
rodent carcinogen” can be learned accurately from data on chem-
icals and assay results? If note if the desired classiﬁcation rules are
not learnable from examples, evenwith the help of guidance based
on biological knowledge e then such a fundamental limitation
cannot necessarily be removed by simply collecting more data, or
by obtaining more knowledge. Rather, it may simply be impossible
to learn accurate predictive classiﬁcation rules or procedures from
available data. To our knowledge, potential fundamental limitations
on the learnability of accurate prediction rules for classifying
chemicals as rodent carcinogens, or for predicting cancer dos-
eeresponse relations based on chemical and in vitro data, have not
previously been carefully studied. Appropriate methods for
addressing fundamental limitations of what is learnable are avail-
able in the machine-learning literature (e.g., using the Probably
Approximately Correct learning frameworks and alternatives), but
these methods have not as yet had much impact on QSAR or sys-
tems biology research used in carcinogenicity prediction systems.
The third question we posed is: What practical constraints limit
predictive performance? This might include things such as
incomplete knowledge of relevant biological mechanisms, or
limited sizes and diversity of training and test data sets. Unlike
fundamental limitations, such practical limitations might be
removed by further scientiﬁc research. This paper and its appendix
touch brieﬂy on practical aspects of training set design, classiﬁca-
tion of chemicals with respect to rodent carcinogenicity, external
test set design and validation, and extrapolation of risk predictions
from tested to untested chemicals. The following analysis focused
L. Anthony (Tony) Cox et al. / Regulatory Toxicology and Pharmacology 77 (2016) 54e6456mainly on the ﬁrst of the questions, i.e., critically evaluating the
performance of a predictive scoring system for rodent carcinoge-
nicity. Questions 2 and 3 e fundamental limitations to predict-
ability and practical issues in developing and testing predictive
scores or classiﬁcations e are also touched on as needed to un-
derstand the strengths and limitations of this predictive model.
For as long as there has been interest in developing algorithms
to screen chemicals for likely in vivo activities based on relatively
inexpensive QSAR and in vitro assay results, there also have been
claims of accurate performance of the systems in current use.
However, these optimistic appraisals have generally not been fol-
lowed by equally good performance on external validation tests
sets, when predictions must be made in advance of knowing the
correct answers (e.g., Benigni and Zito, 2004). Claims of accurate
prediction, therefore, deserve to be scrutinized. We do so for the
recently published National Center for Computational Toxicology
(NCCT) research article (Kleinstreuer et al. 2013) entitled “In vitro
perturbations of targets in cancer hallmark process predict rodent
chemical carcinogenesis;” we refer to this paper and the methods
now as the 2013 rodent chemical carcinogenesis prediction model
(RCCPM). This important contribution to the ﬁeld applies contem-
porary knowledge of the biological “hallmarks of carcinogenesis”
framework to inform selection and combination of high throughput
screening (HTS) assay results that might indicate the activation of
different pathways involved in the process of carcinogenesis. The
authors conclude that “A simple scoring function … applied to an
external test set of 33 compounds with carcinogenicity classiﬁca-
tions from the EPA's Ofﬁce of Pesticide Programs … successfully
(p ¼ 0.024) differentiated between chemicals classiﬁed as
“possible”/“probable”/“likely” carcinogens and those designated as
“not likely” or with “evidence of non-carcinogenicity” (Kleinstreuer
et al., 2013). This model represents a chemical carcinogenicity
prioritization tool supporting targeted testing and functional vali-
dation of cancer pathways.” Our analysis re-examined these ﬁnd-
ings in detail, and sought to independently reproduce them.
2. Methods of analysis
Our analysis was designed to be an independent assessment of
the accuracy and robustness of the 2013 RCCPM (Kleinstreuer et al.,
2013). Before describing our methods, it is important to outline the
structure of that analysis.
The chemicals of primary interest in the 2013 RCCPM were
largely food crop pesticides believed to operate through non-
genotoxic mechanisms to induce one or more of the currently
recognized hallmarks of carcinogenesis, i.e., sustained proliferative
signaling, evasion of growth suppression signals, evasion of im-
mune detection and of destruction of compromised cells, acquisi-
tion of replicative immortality, tumor-promoting inﬂammation,
active invasion and metastasis, induction of neoangiogenesis,
increased genome instability and mutation, evasion of apoptosis,
and deregulation of cellular energetics (Hanahan and Weinberg,
2011). In developing the 2013 RCCPM, the following hypothesis
was stated: “Chemicals that perturb certain cancer-linked targets or
processes in human in vitro HTS assays will have a signiﬁcantly higher
likelihood of being carcinogens, as evidenced by carcinogenicity in the
2-year chronic assays in rodents.” The corresponding null hypothesis
is: Chemicals identiﬁed as perturbing relevant pathways based on the
in vitro HTS assay results are no more likely than other chemicals to
exhibit carcinogenicity in the 2-year chronic assays in rodents. The
authors concluded that their data supported the hypothesis and
allowed for conﬁdent rejection of the null hypothesis. They pro-
posed a prioritization method that scores the carcinogenic poten-
tial of chemicals by counting the number of cancer-associated
endpoints identiﬁed as “signiﬁcantly perturbed” in assay screening.The 2013 analysis began with a search for assays that predict
rodent carcinogenicity. To do so, the authors sought signiﬁcantly
increased univariate odds ratios (ORs) for a chemical being classi-
ﬁed as a rodent carcinogen when the rodent bioassay identiﬁed a
compound as “positive” compared to compounds identiﬁed as
negative for rodent carcinogenicity. ORs were assessed in a training
set of 292 chemicals for which both in vitro assay results and in vivo
2-year rodent chronic assay results were available. These 292
chemicals were ToxCast Phase I chemicals for which 2-year chronic
cancer bioassay data are available from the EPA Toxicity Reference
Database (ToxRefDB, http://actor.epa.gov/toxrefdb/). This database
classiﬁes each chemical as positive or negative for preneoplastic or
neoplastic lesions in rats (232 chemicals) and mice (223 chemicals,
200 of which overlap with those for rats). Only the most common
cancer endpoints were included for each species, deﬁned as those
endpoints occurring for at least 20 chemicals. The common cancer
histopathological endpoints used in the analysis were: 1) liver
preneoplasia or neoplasia in mice; 2) lung preneoplasia in mice; 3)
spleen preneoplasia in mice; 4) kidney preneoplasia in rats; 5) liver
preneoplasia or neoplasia in rats; 6) testes preneoplasia or
neoplasia in rats; and 7) thyroid preneoplasia or neoplasia in rats.
The 292 chemicals used in developing the 2013 RCCPM are listed in
Supplementary Table 1 of Kleinstreuer et al. (2013).
2.1. Veriﬁcation of the 2013 RCCPM cancer classiﬁcations
The ﬁrst step in our analysis was to independently replicate and
validate the approach used in developing the 2013 RCCPM before
attempting to quantify the predictivity of the HTS data for rodent
carcinogenicity. We obtained data and software from the article
publication site, the study authors, and the National Pesticide In-
formation Center. Data ﬁles used in the study were obtained from
the journal article publication site (http://toxsci.oxfordjournals.org/
content/131/1/40/suppl/DC1). The ﬁles listed in the article were
referred to as Supplementary Tables 1e6 (Table 1 below). We
converted the pdf ﬁles File007, File008, File010 to data ﬁles via a
combination of OCR software and manual correction.
Upon request, the corresponding author, Dr. Richard Judson,
sent the software used in the study and the full set of the NCCT
input and output tables in electronic form. Table 2 lists several of
these ﬁles which proved to be key to our validation exercise.
As described in the article, a database of 309 unique chemicals
was developed and 292 of those chemicals were ﬂagged for usage.
Of the 292 chemicals used, 60 had no rat-related in vivo cancer data
(232 remaining), while 69 had nomouse-related in vivo cancer data
(223 remaining). The database provided AC50 data values for 664
unique assays for each of the 309 chemicals. There were 673 assay
names in the gene mapping ﬁle. Six of the 664 assay columns in the
AC50 data ﬁle had names that were not listed in the gene mapping
ﬁle. All AC50 values for these six chemicals were zero; however, as
was also true of many other assays, this did not impact the results.
For the 2013 RCCPM test data set, 60 chemicals were identiﬁed,
listed in their Table 1 (“Summary of cancer hazard model for
chemicals not included in the training set for rat endpoints”), that
had not been used in constructing their risk prediction model, but
that had in vitro assay results. From these 60 chemicals, they
selected as their ﬁnal external validation test set a subset of 33
chemicals that had EPA Ofﬁce of Pesticide Programs (OPP) human
carcinogenicity classiﬁcations (shown in the last column of their
Table 1). They note that “these ‘human’ classiﬁcations are in reality a
summary of data from [largely] rodent studies and so are comparable
with the data used in developing the model.” For purposes of testing
and validating the 2013 RCCPM, the investigators pooled cancer
classiﬁcation used by EPA by assigning a value of “1” to any
chemical with a classiﬁcation containing the words “Likely,”
Table 1
Data ﬁles from the journal website.
File as named in Kleinstreuer et al. (2013) File as named at website Contents
Supplementary Table 1 toxsci_12_0526_File007.pdf chemical codes/names and indicator ﬂag of use in study
Supplementary Table 2 toxsci_12_0526_File008.pdf table of hits by chemical and in-vivo endpoint
Supplementary Table 3 toxsci_12_0526_File009.xlsx AC50 values by chemical and assay
Supplementary Table 4 toxsci_12_0526_File010.pdf Gene mappings and process counts by assay
Supplementary Table 5 toxsci_12_0526_File011.pdf Figure 3 diagram
Supplementary Table 6 toxsci_12_0526_File012.xlsx research article database
Table 2
Additional key ﬁles sent by NCCT on request.
File name Contents
Hallmark2.R R software used to generate odds ratios, identify signiﬁcant variables, and compute predictive scores.
ORforestData_assay.txt Odds ratios, LCIs, UCIs, and 2  2 contingency table values for individual assay-endpoint combinations
ORforestData_assay_perms.txt Odds ratios, LCIs, and UCIs for “permuted” chemicals, one set for each endpoint.
CancerPred_all_ALL.txt Cancer prediction scores for all 292 chemicals (similar to Table 1, but expanded to cover training chemicals)
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as “Not Likely” or “Evidence of non-carcinogenicity.” Chemicals,
with classiﬁcations such as “Not classiﬁable” or “Suggestive evi-
dence,” or “Insufﬁcient data” were excluded from their analysis.
The data provided to us by NCCT did not include an electronic
version of Table 1 from the 2013 paper, i.e., the external validation
test data set. We therefore independently obtained a pdf document
from the National Pesticide Information Center1 that contains the
cancer classiﬁcation for most of the chemicals used in this study,
and converted that ﬁle to an electronic format for use in our
analysis. Thus, the ﬁrst step in our analysis involved reviewing each
entry in Table 1 of the published paper to verify the accuracy of the
cancer classiﬁcations.
2.2. Reproduction of the 2013 RCCPM methodology
The next step was to reproduce the methodology, as far as
possible, based on the documentation and the additional data ﬁles
and software obtained from the authors. We replicated these
methods as follows.
2.2.1. Replicating selection of predictors based on signiﬁcant assay-
endpoint combinations
In developing the 2013 RCCPM, the investigators determined
which chemical/assay combinations would be considered “signiﬁ-
cant” for predicting carcinogenic potential using odds ratio values,
and their 95% conﬁdence intervals, from two sources, explained
next: 1) univariate odds ratios, and 2) average “permuted” odds
ratios (see paragraph 3 of Materials and Methods in the article). In
several places where the article's discussion was insufﬁcient for us
to reproduce results, the R software code provided by the authors
gave the needed clariﬁcation.
They ﬁrst computed an odds ratio for each assay/endpoint
combination (664  11) using the vector of AC50 values for the
assays (with non-zeros converted to “1” and the 0/1 vector of
endpoint values. In accordance with the study procedures, any
chemical rows corresponding to an “NA” endpoint result, and any
assay column with fewer than 10 hits over the 292 chemicals used
in the training set, were eliminated. We used software indepen-
dently coded in the Python programming language to check1 http://npic.orst.edu/chemicals_evaluated.pdf, “Chemicals Evaluated for Carci-
nogenic Potential” (Nov 2012), published by the EPA Ofﬁce of Pesticide Programs
(OPP).whether we could reproduce the study results.
2.2.2. Replicating the univariate odds ratios calculations
For each assay-endpoint combination, we fed the two binary
vectors into a Python function that computed contingency table
values n00, n01, n10, and n11 corresponding to the counts of vector
elements falling into each cellnxy (with the convention that
x ¼ assay, y ¼ endpoint). For instances where all 4 cell counts were
non-zero, the function returned the odds ratio:
OR ¼ n00*n11/n01*n10,
and the standard error:
SE ¼ sqrt(1/n00 þ 1/n11 þ 1/n01 þ 1/n10)
In the case of any zero cell elements, OR ¼ 1 and SE ¼ 0 was
returned (the computationwas indeterminate and ﬂagged for non-
use). We computed the lower and upper 95% conﬁdence intervals
using the following standard asymptotic formulas:
LCI95 ¼ exp(log(OR) e 1.96*SE)
UCI95 ¼ exp(log(OR) þ 1.96*SE)
These computations, veriﬁed as the same used by the de-
velopers of the 2013 RCCPM via the software code, correspond to
the “Wald” method for calculating odds ratios based on a normal
approximation to the log odds ratios. Other methods are available,
including the exact Fisher (conditional maximum likelihood),
midpoint (median unbiased), and small sample adjusted methods.
Such alternative methods are appropriate when one or more cells
have small values, as happens often in this study. These alternative
methods are readily available in the R language epitools module.2
They often provided wider conﬁdence intervals than the Wald
method, potentially producing fewer false positives (in which an
artiﬁcially narrow conﬁdence interval wrongly excludes the null
hypothesis of no signiﬁcant relation, OR ¼ 1).
2.2.3. Replicating the permuted odds ratios calculations
In developing the 2013 RCCPM, the investigators also described
odds ratios, one per endpoint, that were determined by “permuting2 (http://cran.r-project.org/web/packages/epitools/index.html)
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conﬁdence intervals for each endpoint were said to be calculated
from the “OR distribution across all assays.” The precise meaning of
these statements, described below, was made apparent by studying
the provided R software code.
A single “permutation” involves taking a random permutation of
the 0/1 endpoint vector, and computing the odds ratios for the
permuted vector for each of the 664 chemical assays. To obtain the
result for a single endpoint, 10,000 permutations are performed,
and the odds ratio vectors concatenated into a single long vector
(any indeterminate elements are removed). The vector is then
sorted and the elements at 0.025 and 0.975 of the vector length are
extracted. These values determine the 95% conﬁdence intervals
associated with that endpoint. We replicated this procedure in
Python using the same inputs.2.2.4. Replicating the signiﬁcance test for predictor variable
selection
To replicate the signiﬁcance test for selection of predictor vari-
ables, we followed the same criteria for demonstrating signiﬁcance:
“Assayendpointpairswere considered signiﬁcant if theCI for thepair
did not include 1.0 (i.e., an OR of ‘no evidence of association’), and if
thepointestimate of theORwasoutsideof the95%permutation test-
derived CI for the endpoint.” Applying their additional ﬁlter of
including only cases with 3 or more true positives (n11  3), we
replicated the data underlying their Fig. 1 (odds ratio forest graph).
Table 3 below summarizes the computed values underlying Fig. 1.Fig. 1. (from Kleinstreuer et al., 2013) Forest plot showing the mean OR and CIs for each sig
three or more true positives are shown. The colored circles give the point estimate of the OR
test 95% CI. The linkage to types of processes is indicated by the color of the OR circle: dark
related, and white is other. The assay name is listed at the far left. The associated gene, ge
lesions, 3 ¼ neoplastic lesions) are indicated to the right. A darker line indicates overlap of2.2.5. Replicating the cancer hazard scoring
The identiﬁed “signiﬁcant” assay-endpoint combinations were
used as predictors for calculating a cancer hazard score for each
chemical. The score for each chemical is deﬁned simply as a count
of how many assays were activated, i.e., had non-zero AC50 values,
that coincide with a signiﬁcant (rodent-related) assay-endpoint
pair. Table 1 of the published paper lists the resulting total scores,
along with a breakdown by endpoint type for each of the 60
chemicals.2.2.6. Replicating the comparison of the model-predicted cancer
hazard scores to EPA’S binary cancer classiﬁcations
The key research question that the steps in our analysis were
intended to provide data to answer was: How well do the
computed cancer hazard scores predict the externally derived 0/1
cancer potential classiﬁcation scores provided by EPA-OPP? As
previously discussed, the hazard scores were generated by applying
the scoring procedure (i.e., count the number of relevant activated
assays), as developed from the training set of 232 chemicals with
(rat and mouse) in vivo endpoint information, to a test set of 60
chemicals without in vivo endpoint information (of which 33 had
externally provided cancer classiﬁcation data). To compare the
predictive scores (counts) to the externally provided EPA-OPP bi-
nary classiﬁcations, the developers of the 2013 RCCPM performed a
ManneWhitney test (also known as Mann-Whitney-Wilcoxon rank
sum test or MWW) to assess the statistical signiﬁcance of the as-
sociation between the 33 cancer hazard scores and the binaryniﬁcant association between in vitro assay and in vivo endpoint. Only associations with
and whiskers give the 95% CI. The gray bars indicate the endpoint-speciﬁc permutation
gray is cancer hallmark-related, light gray is XME (xenobiotic metabolizing enzymes)-
ne-related process, species, cancer type, and cancer severity level (2 ¼ preneoplastic
the assay-speciﬁc and the endpoint CIs.
Table 3
Replication of signiﬁcant assay endpoint pairs and OR values.
Assay GeneSymbol EndPoint LCI OR UCI PermLCI PermUCI Truepositives
NVS_GPCR_hORL1 OPRL1 RTroid2Pre 3.25 16.76 86.55 0.30 2.94 6
NVS_ENZ_hPDE5 PDE5A Rliver3Neo 2.17 11.56 61.46 0.31 3.60 3
BSK_BE3C_tPA_up PLAT RLiver2Pre 2.07 7.17 24.82 0.30 2.65 8
NVS_ADME_hCYP3A4 CYP3A4 RLiver2Pre 2.07 7.17 24.82 0.30 2.65 8
CLZD_HMGCS2_48 HMGCS2 Rliver3Neo 1.76 5.68 18.37 0.31 3.60 5
NVS_ENZ_rMAOAC Maoa RKidney2Pre 1.45 5.50 20.88 0.29 3.23 4
NCGC_AR_Antagonist AR Rliver3Neo 1.92 5.36 14.98 0.31 3.60 7
CLZD_SLCO1B1_48 SLC01B1 Rliver3Neo 1.47 5.28 18.95 0.31 3.60 4
CLM_MicrotubuleCSK_Destabilizer_24hr NAGene RTroid2Pre 1.25 5.22 21.85 0.30 2.94 4
BSK_SAg_MCP1_up CCL2 MSpleen2Pre 1.17 4.94 20.86 0.32 3.80 3
BSK_SM3C_MCP1_up CCL2 Rliver3Neo 1.66 4.88 14.29 0.31 3.60 6
CLM_p53Act_72hr TP53 RTestes2Pre 1.64 4.85 14.32 0.30 3.25 6
BSK_3C_Vis_down Cytotox MLung2Pre 1.76 4.85 13.34 0.31 3.88 13
CLZD_HMGCS2_48 HMGCS2 RLiver2Pre 1.64 4.62 13.07 0.30 2.65 9
BSK_SM3C_MCP1_up CCL2 RLiver2Pre 1.84 4.53 11.16 0.30 2.65 12
CLM_p53Act_72hr TP53 RTestes3Neo 1.42 4.46 14.00 0.30 3.53 5
BSK_KF3CT_ICAM1_down ICAM1 MSpleen2Pre 1.25 4.36 15.27 0.32 3.80 4
CLM_Hepat_Steatosis_1hr NAGene MSpleen2Pre 1.25 4.36 15.27 0.32 3.80 4
CLM_CellLoss_72hr Cytotox RTroid3Neo 1.59 4.30 11.65 0.30 3.12 26
CLZD_ABCG2_24 ABCG2 MSpleen2Pre 1.04 4.30 17.73 0.32 3.80 3
BSK_4H_uPAR_down PLAUR Rliver3Neo 1.03 4.23 17.35 0.31 3.60 3
ATG_CMV_CIS NAGene Rliver3Neo 1.03 4.23 17.35 0.31 3.60 3
CLZD_HMGCS2_24 HMGCS2 Rliver3Neo 1.03 4.23 17.35 0.31 3.60 3
ATG_CMV_CIS NAGene RLiver2Pre 1.20 4.10 14.01 0.30 2.65 6
CLZD_UGT1A1_6 UGT1A1 RKidney2Pre 1.14 4.08 14.58 0.29 3.23 4
CLM_OxidativeStress_24hr H2AFX Rliver3Neo 1.31 4.08 12.68 0.31 3.60 5
CLM_CellLoss_72hr Cytotox RTroid2Pre 1.72 4.07 9.66 0.30 2.94 33
CLM_MitoMembPot_24hr EMGene RTroid3Neo 1.78 4.07 9.32 0.30 3.12 12
BSK_BE3C_IL1a_down IL1A RLiver2Pre 1.39 4.02 11.66 0.30 2.65 8
CLM_p53Act_72hr TP53 RTroid3Neo 1.30 3.78 10.97 0.30 3.12 6
NVS_ADME_hCYP3A4 CYP3A4 RTroid2Pre 1.13 3.78 12.58 0.30 2.94 5
NCGC_AR_Antagonist AR RTestes3Neo 1.32 3.77 10.77 0.30 3.53 6
CLM_Hepat_CellLoss_1hr Cytotox RTroid2Pre 1.42 3.75 9.90 0.30 2.94 8
BSK_KF3CT_IL1a_down IL1A RTroid2Pre 1.62 3.69 8.37 0.30 2.94 12
CLZD_SLCO1B1_48 SLC01B1 RKidney2Pre 1.03 3.61 12.63 0.29 3.23 4
CLM_OxidativeStress_24hr H2AFX RLiver2Pre 1.42 3.61 9.20 0.30 2.65 10
BSK_KF3CT_ICAM1_down ICAM1 RTroid2Pre 1.20 3.59 10.74 0.30 2.94 6
NVS_ADME_hCYP3A4 CYP3A4 RTroid3Neo 1.01 3.57 12.68 0.30 3.12 4
CLM_Hepat_Steatosis_1hr NAGene RTestes2Pre 1.03 3.56 12.32 0.30 3.25 4
CLM_p53Act_72hr TP53 RTroid2Pre 1.26 3.49 9.66 0.30 2.94 7
CLZD_ABCG2_48 ABCG2 MLiver2Pre 1.34 3.46 8.96 0.33 2.65 14
BSK_SM3C_Thrombomodulin_up THBD RLiver2Pre 1.46 3.42 8.02 0.30 2.65 12
NCGC_AR_Antagonist AR MLiver2Pre 1.32 3.26 8.06 0.33 2.65 15
CLM_Hepat_NuclearSize_24hr NAGene RLiver2Pre 1.30 3.26 8.15 0.30 2.65 10
BSK_SM3C_MIG_down CXCL9 RTroid2Pre 1.09 3.21 9.42 0.30 2.94 6
CLM_Hepat_CellLoss_1hr Cytotox RTroid3Neo 1.13 3.21 9.10 0.30 3.12 6
CLM_OxidativeStress_1hr H2AFX RTroid2Pre 1.17 3.18 8.68 0.30 2.94 7
NVS_ADME_rCYP2A2 Cyp2a2 MLiver2Pre 1.21 3.17 8.29 0.33 2.65 13
BSK_hDFCGF_IP10_down CXCL10 RTroid2Pre 1.52 3.05 6.13 0.30 2.94 23
NVS_ADME_hCYP2J2 CYP2J2 MLiver2Pre 1.20 3.00 7.50 0.33 2.65 14
NVS_ADME_hCYP1A1 CYP1A1 MLiver2Pre 1.09 2.89 7.65 0.33 2.65 12
BSK_BE3C_MIG_down CXCL9 MLiver2Pre 1.09 2.89 7.65 0.33 2.65 12
BSK_BE3C_uPAR_down PLAUR MLiver2Pre 1.09 2.89 7.65 0.33 2.65 12
CLZD_ABCB1_24 ABCB1 MLiver2Pre 1.20 2.88 6.90 0.33 2.65 15
BSK_BE3C_MMP1_up MMP1 RLiver2Pre 1.27 2.83 6.27 0.30 2.65 13
CLM_p53Act_72hr TP53 RLiver2Pre 1.03 2.77 7.40 0.30 2.65 8
CLM_Hepat_DNADamage_24hr Apoptosis RLiver2Pre 1.12 2.73 6.62 0.30 2.65 10
BSK_SAg_IL8_down IL8 RKidney2Pre 0.09 0.27 0.82 0.29 3.23 4
NVS_ADME_hCYP2C19 CYP2C19 MSpleen2Pre 0.07 0.25 0.88 0.32 3.80 3
BSK_3C_uPAR_down PLAUR RKidney2Pre 0.07 0.25 0.84 0.29 3.23 3
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hypothesis that two populations have the same distribution of
scores against the alternative hypothesis that one tends to have
larger values than the other. The MWW test was originally devised
for continuous variables (here we have binary and integer vari-
ables), but in practice has been applied to ordered categorical data
as well. The authors reported a signiﬁcant correlation (value not
provided) with a signiﬁcance level of 0.024 from their MWW test.
Since this is well under the conventional 0.05 level, they concluded
that their methodology is signiﬁcantly predictive in the externalvalidation test set: “We have demonstrated an approach to identify
and test molecular pathways or processes that, when perturbed by
a chemical, raise the likelihood that the chemical will be a carcin-
ogen.…A simple scoring function built from these associated genes
was signiﬁcantly predictive of cancer hazard classiﬁcations for an
external test set.” Therefore, we performed an independent anal-
ysis to check the conclusion.
First, we noted that the MWW test is not applicable when there
are ties in the ranks of the values, of which there were many in the
2013 RCCPM dataset. The test cannot be relied upon to determine a
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the variance of the MWW test statistic can be adjusted in the
presence of ties, this adjustment always results in an increase in the
test statistic and smaller P values” (McElduff et al., 2010).
It was not clear what implementation of MWWwas used by the
developers of the 2013 RCCPM, but the R function “wilcox.test”
provides a warning message (“In wilcox.test.default cannot
compute exact p-value with ties” when the data contains tied
values.) We, therefore, applied a different test e the Kendall tau-b
correlation test e that adjusts for tied values. We used the stan-
dard implementation available in the Python scipy library.3 We ﬁrst
performed the Kendall tau-b test (with adjustments for ties) on the
data as reported in Table 1 of Kleinstreuer et al. (2013), without
corrections. Then, to address the discrepancies noted in chemical
classiﬁcation (see 3.1) and scoring (see 3.4), we used the same test
on the corrected dataset where we removed methylene bis(thio-
cyanate) (MITC) from the external validation test set, and added
etridiazole, along with including the minor score correction for
oxyﬂuorfen.
2.2.7. Additional analysis considering human relevance of animal
data
In determining potential cancer risk to humans, EPA seeks to use
relevant and reliable information to reach conclusions about po-
tential hazards and risks to humans based on information about the
nature and incidence of the pathological responses, species speci-
ﬁcity and sensitivity, and dose response. In the 2013 RCCPM,
however, human relevance of speciﬁc types of cancer responses in
animals was not considered before classifying a chemical as posi-
tive or negative for carcinogenicity. Therefore, we examined the
carcinogen classiﬁcation for each of the chemicals in the 2013
RCCPM dataset from the standpoint of possible human relevance.
To perform this analysis, we identiﬁed sources for EPA discussions
of cancer hazard for each of the 154 chemicals scored as “1,” evi-
dence of carcinogenicity in the 2013 RCCPM publication, and
considered whether the human relevance discussions should affect
the classiﬁcation. The sources accessed for EPA discussions
included the OPP summary document discussed previously, avail-
able Registration Eligibility Decision (RED) documents, and publicly
available cancer hazard assessments that could be accessed elec-
tronically. Our ﬁndings were compiled into a table that listed each
chemical, the EPA ﬁndings, and whether we judged the 2013
RCCPM cancer listing was appropriate for humans.
3. Results
3.1. Veriﬁcation of the carcinogenicity classiﬁcations of the
chemicals in the 2013 RCCPM dataset
Since the 2013 RCCPM analysis cited the EPA rodent carcino-
genicity classiﬁcations as a data source, verifying these data was an
important ﬁrst step. We were able to independently conﬁrm (see
Supplementary Materials 1) most (58 of 60) of the carcinogenicity
classiﬁcations in Table 1 of the published work (Kleinstreuer et al.,
2013) as matching those provided by OPP. Of the 60 chemicals, we
found discrepancies for two chemicals. For these chemicals,
methylene bis(thiocyanate) and etridiazole, the classiﬁcations re-
ported in the 2013 RCCPM publication, and attributed to OPP,
differed from those that we found in the EPA/OPP published data. In
the case of methylene bis(thiocyanate) [CASRN 6317-18-6] (MITC),
Table 1 of the published paper included the chemical with a score of3 http://docs.scipy.org/doc/scipy/reference/generated/scipy.stats.mstats.
kendalltau.html.1 based on reference to an EPA carcinogenic potential classiﬁcation
of “Likely to be carcinogenic e based on metam sodium data.”
Review of the EPA/OPP document, however, reveals that EPA has
concluded that “There are insufﬁcient data to characterize the
cancer risk of MITC,” a classiﬁcation made in 2009. The computed
cancer hazard score for that MITC is relatively high, at 16. Although
MITC is a breakdown product of metam sodium, it is not formed
quickly and the use of the metam sodium risk information as a
surrogate for it is scientiﬁcally questionable.4 Indeed, separate EPA/
OPP documentation explicitly states that “it is not appropriate to
quantify MITC cancer potential using the metam sodium cancer
slope factor… .”5 Clearly, the classiﬁcation of MITC in Table 1 of the
published paper does notmatch that provided by OPP. In the case of
etridiazole [also called Terrazole, CASRN 2593-15-9], Table 1 of the
article indicates that there is “No data,” resulting in a score of “0” for
the chemical. Yet, the EPA/OPP document classiﬁes the chemical as
“Group B e Probable Human Carcinogen” (report date of 1999). The
OPP classiﬁcation was stated to be based on the occurrence of
multiple tumor types in male and female rats including the in-
duction of a rare bile duct tumor (cholangiocarcinoma), non-
neoplastic lesions observed in similar target organs that lend sup-
port to the association of etridiazole exposurewith the induction of
tumors, increased absolute and relative liver weight in male rats,
hepatocytomegaly in male rats, clear, basophilic, and eosinophilic
cellular alterations in rats of both sexes, cholangiectasis in female
rats, centrilobular pigmentation in female rats, spongiosishepatis of
the liver of male rats, testicular interstitial cell hyperplasia in rats,
and positive mutagenicity data. The cancer hazard score for this
chemical computed by the 2013 RCCPM was zero. As a result, the
fact that it was misclassiﬁed as having “No data” prevented an
important discrepancy between this prediction and the multiple
tumor types observed in rats from being taken into account.
Although classiﬁcations for 58 of the 60 chemicals were veriﬁed,
the discrepancies for MITC and etridiazole had a signiﬁcant impact
on the study results (see discussion below).
3.2. 2 Replicating the univariate odds ratio calculations
We veriﬁed that our software was computing the same odds
ratios and conﬁdence intervals as the published paper (Kleinstreuer
et al. 2013) by checking against the intermediate output ﬁles pro-
vided by Dr. Judson. Thus, we were able to replicate the univariate
ORs calculated in the 2013 RCCPM publication.
3.3. Replicating the permuted odds ratios calculations
Table 4 below, produced using our Python code, provides results
very similar (but not identical) to those of the original authors. The
small differences observed above are plausibly due to differences in
random number generation which resulted in different permuta-
tion sets; they did not affect the selection of signiﬁcant assay-
endpoint combinations.
3.4. Replicating the signiﬁcance test for predictor variable selection
and the cancer hazard scoring
Our replication identiﬁed two signiﬁcant assay-endpoint com-
binations that were not included in the 2013 RCCPM article, prob-
ably because of a “#” symbol in the ﬁle appeared to have caused




Comparison of computed versus NCCT-provided endpoint CI values.
End point Computed LCI NCCTLCI Computed UCI NCCT UCI
MLiver2Pre 0.326 0.326 2.65 2.65
MLiver3Neo 0.279 0.274 2.80 2.80
MLung2Pre 0.310 0.296 3.88 3.88
MSpleen2Pre 0.316 0.304 3.80 3.80
RKidney2Pre 0.291 0.291 3.23 3.23
RLiver2Pre 0.302 0.302 2.65 2.65
Rliver3Neo 0.314 0.314 3.60 3.60
RTestes2Pre 0.303 0.303 3.25 3.25
RTestes3Neo 0.304 0.310 3.53 3.53
RTroid2Pre 0.303 0.303 2.94 2.92
RTroid3Neo 0.299 0.299 3.12 3.03
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42874-03-3) shown in Table 1 of the 2013 paper should have had a
total score of 11 versus the 9 shown, and the Liver 2 and Liver 3
columns in that row should have had 1 added to them, making
them 3 and 2 respectively. These changes did not have a signiﬁcant
impact on the results (discussed further below).
Overall,wewere able to reproducemost of the variable-selection
process used by the developers of the 2013 RCCPM. However, we do
not endorse this approach of selecting variables based on odds ra-
tios.We recommend insteadusingBayesianModel Averaging, cross-
validation, or other model ensemble methods to help overcome
model selection, multiple comparison, and over-ﬁtting biases that
can inﬂate false-positive rates and reduce generalization accuracy.
These sources of avoidable bias and error do not appear to have been
adequately controlled in the OR-based selection procedure applied
in the development of the 2013 RCCMP. With respect to cancer
hazard scoring, using our Python software, we reproduced all of the
scores, with the minor exception just discussed.
3.5. An alternative comparison of the model-predicted cancer
hazard scores to RCCPM binary cancer classiﬁcations
We independently analyzed the predictivity of the model-based
scores using the Kendall tau-b test (with adjustments for ties). ForFig. 2. The fraction of chemicals classiﬁed as rodent carcinogens is 100% if athe uncorrected data used by Kleinstreuer et al., this test provided a
correlation coefﬁcient of 0.30 and a p-value of 0.0453, larger than
the p value of 0.024 they reported in 2013, but still slightly less than
0.05. For comparison, we also derived 0/1 classiﬁcation data for 176
of the 232 chemicals in the training data set using the EPA/OPP
document, and found that the test provided a correlation of 0.20
with a p value of 0.00188, that is, a highly signiﬁcant correlation.
Then, we used the same test on the corrected dataset where we
removed methylene bis(thiocyanate) (MITC) from the external
validation test set, and added etridiazole, along with including the
minor score correction for oxyﬂuorfen. This test provided a corre-
lation coefﬁcient of 0.20 and a p value of 0.09 that is not signiﬁcant
at the conventional 5% signiﬁcance level (though it is at the 10%
signiﬁcance level). If both MITC and etridiazole are included, the
Kendall tau-b test yields a correlation coefﬁcient of 0.25 and a p
value of 0.09. Thus, the rejection of the null hypothesis of no sta-
tistically signiﬁcant association between scores and binary external
classiﬁcations at the conventional 5% signiﬁcance level appears to
depend crucially on the uncorrected classiﬁcations of two chem-
icals and use of the MWW test without needed corrections for ties.
That a statistical test for association between predictive scores
and the binary classiﬁcations used in the 2013 RCCPM is not sig-
niﬁcant at the 5% level does not mean that there is no valid or useful
predictive relation between the scores and the classiﬁcation. It only
means that association may not be the best way to describe that
relation. And, indeed, the ordinal association, while statistically
signiﬁcantly greater than zero, is relatively weak (Kendall tau-
b¼ 0.25). This might suggest that the classiﬁcationmodel, although
better than random (null hypothesis is rejected), still has only very
limited predictive power overall. A more nuanced understanding of
the performance of the predictive model can be obtained relatively
simply in this case, although more sophisticated analysis is
required in general (e.g., http://www.ncbi.nlm.nih.gov/pubmed/
24240655Kerr et al., 2014). Fig. 2 directly plots the fraction of
chemicals classiﬁed by EPA as possible, probable, or likely rodent
carcinogens against the predictive score (i.e., the count of the
number of HTS assays, grouped by the 11 histopathological end-
points, as previously discussed). Among 25 test set chemicals withnd only if the predictive score (count of positive HTS assays) exceeds 6.
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carcinogens; prediction accuracy emulated chance alone. Among
the remaining 8 chemicals, having scores of 7 or more, 100% are
classiﬁed as rodent carcinogens. The relation is not smoothly
increasing, and hence ordinal association measures may not be the
best way to characterize it.
Fig. 2 indicates that the interpretation in the 2013 RCCMP
publication “We have demonstrated an approach to identify and test
molecular pathways or processes that, when perturbed by a chemical,
raise the likelihood that the chemical will be a carcinogen” is too
simple, in that it appears to be only the joint activation of at least 7
of these pathways or processes that predicts signiﬁcantly increased
risk of rodent carcinogenicity. Likewise, the statement “A simple
scoring function built from these associated genes was signiﬁcantly
predictive of cancer hazard classiﬁcations for an external test set” is
true, but with the caveat that only scores of 7 or more are signiﬁ-
cantly predictive of cancer hazard classiﬁcations.
In summary, rather than testing the signiﬁcance of measures of
ordinal association, an alternative, simple characterization of the
predictive relation between HTS-derived scores and EPA classiﬁ-
cations of the rodent carcinogenicity of these pesticides is that the
pesticides with 7 or more “hits” (joint activation of HTS responses
in at least 7 of the pathways or processes associated with the 11
histopathological responses) are very likely to be classiﬁed as ro-
dent carcinogens. This high-scoring fraction, the “extreme” sub-
stances with 7 or more “hits,” comprised 8/33, or just under 25%, of
the test data set. For substances exhibiting six or fewer “hits,”
prediction accuracy was shown to be no better than chance.
3.6. Consideration of the human relevance of animal cancer data
In developing the 2013 RCCPM, the investigators extracted in-
formation from ToxRefDB for chemicals with entries corresponding
to preneoplastic and carcinogenic pathologies in mouse and rat,
without consideration for human relevance of a ﬁnding. For mice,
the data extracted corresponded to effects in mice classiﬁed as
“liver preneoplastic,” “liver neoplastic,” “lung preneoplastic,” and
“spleen preneoplastic” and in rats “kidney preneoplastic,” “liver
preneoplastic,” “liver neoplastic,” “testes preneoplastic,” “testes
neoplastic,” “thyroid preneoplastic,” and “thyroid neoplastic”
(Kleinstreuer et al., 2013, Supplementary Table 1). However, mouse
liver tumorigenesis often lacks relevance to human cancer risk, can
occur at high background rates, or may have doseeresponse
thresholds and modes of action not relevant to human cancer
(Maronpot, 2009). Likewise, thyroid lesions in rats, both preneo-
plastic and neoplastic, often result from mechanisms of little to no
concern for human health due to well-recognized species differ-
ences in sensitivity and mechanisms which alter thyroid hormone
homeostasis in the rat but not in humans (Hill et al. 1998). Similarly,
testicular preneoplastic and neoplastic lesions in rats are not
indicative of substantive cancer hazard to humans (Cook et al.
1999). Of the 11 rodent bioassay histopathological endpoints used
to develop the 2013 RCCPM, as many as 7 are in organs for which
certain types of preneoplastic and neoplastic lesions are well
known to be of little to no relevance to humans (liver preneoplasia
or neoplasia in male mice, kidney preneoplasia in male rats, testes
preneoplasia or neoplasia in rats and thyroid preneoplasia or
neoplasia in rats).
To determine potential cancer risk to humans, EPA seeks to
consider selected relevant and reliable information, and to reach
conclusions on potential hazards and risks to humans based on
information about the nature and incidence of the pathological
responses, species speciﬁcity and sensitivity, and dose response.
The predictive relation in Fig. 2 above classiﬁes several substances
as positive for rodents even when EPA concluded that the level ofevidence does not indicate a “likely” or “sufﬁcient” or “probable”
cancer risk to humans (i.e., consideration of human relevance).
Supplemental Materials 2 summarizes our ﬁndings when the
carcinogen classiﬁcation for each of the chemicals from the 2013
RCCPM publication is assessed from the standpoint of possible
human relevance. Our results showed that of the rodent carcino-
genicity classiﬁcations used in the 2013 RCCPM for 155 chemicals,
105 might be changed if the hazard classiﬁcation were to be made
more relevant to humans. This was an important ﬁnding given that
regulatory authorities routinely consider human relevance when
examining rodent cancer bioassay data andmaking decisions about
cancer risk. It is well established that not all animal ﬁndings are
relevant to human cancer risk assessment (Cohen et al. 2003;
Proctor et al. 2007; Cohen and Arnold, 2011). Factors that can
affect the relevance of animal cancer bioassay ﬁndings to human
risk assessment include the use of high doses throughout the life of
the animal, mechanisms related to toxicokinetic differences be-
tween rodents and humans, and physiological and anatomical
differences. Gaylor (2005) concluded that the rodent carcinogen
bioassay structured around the Maximum Tolerated Dose “is not
distinguishing between true carcinogens and non-carcinogens.”
Thus, while there may be sufﬁcient evidence of a carcinogenic
response in bioassays using lab animals, one cannot simply assume
such results indicate a true carcinogenic hazard to humans from
environmentally relevant exposures (Borgert et al., 2015).
4. Conclusions
Within the HTS Scientiﬁc Conﬁdence Framework (SCF) pro-
posed in Cox et al. 2014 and reﬁned in Patlewicz et al., 2015, the
analyses we conducted equate to the qualiﬁcation step e the
assessment of a prediction model derived from the HTS assays. The
qualiﬁcation step in the SCF includes evaluation of appropriate
measures of goodness-of-ﬁt, robustness and performance as well as
characterizing known limitations of the prediction model. Overall,
we found that the details provided in the 2013 RCCPM publication,
when supplemented with information from the authors, were
sufﬁcient to facilitate review, reconstruction and independent
veriﬁcation of results. We were able to replicate most of the data
and results reported in the published work of Kleinstreuer et al.
(2013). The key conclusions of the 2013 RCCPM, however, proved
to be very sensitive to the uncertain classiﬁcations of two chem-
icals, and the choice of statistical methods. The carcinogenic po-
tential classiﬁcations for 2 of 60 chemicals differed from those in
EPA/OPP published data (http://npic.orst.edu/chemicals_evaluated.
pdf), and a different classiﬁcation would be needed for most
chemicals if the goal were to identify potential human carcinogens.
The Mann-Whitney-Wilcoxon rank sum test used was not appro-
priate for the data due to many tied ranks. Correcting these two
chemical classiﬁcations and applying a test (Kendall tau-b) that
correctly adjusts for ties, we found that the HTS-based cancer
hazard scores no longer signiﬁcantly predict in vivo cancer results.
A change of classiﬁcation to a single chemical can change the
original study conclusion, which is therefore not robust. This
outcome suggests a clear need for more robust predictions (e.g.,
based on application of current model ensemble machine learning
methods), and highlights the potential value of using multiple
subsets of training data to achieve predictive models and quanti-
tative conclusions that are less sensitive to minor changes in
chemical classiﬁcations and statistical methods.
The replication and reanalysis results presented here raise the
question of the utility of the 2013 RCCPM. On the one hand, even
though results are not statistically signiﬁcant at a conventional 0.05
signiﬁcance level, the fact that they are statistically signiﬁcant at
the 0.10 level might be taken as encouraging. On the other hand, in
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icals with a score of 7 or more were all classiﬁed as rodent car-
cinogens (in the test set), but each chemical with a score of 0e6 had
one or more chemicals that are not rodent carcinogens. Thus, the
simple scoring system proposed in the 2013 RCCPM only appears to
have genuine predictive power for scores of at least 7 (about 25% of
the chemicals examined). For the remaining approximately 75% of
the chemicals, it appears that the RCCPM scoring system does not
adequately predict cancer hazard classiﬁcations, consistent with
the poor performance of previous systems in predicting rodent
carcinogens in external validation studies (e.g., Valerio et al. 2010;
Walmsley and Billinton, 2011; Benigni and Zito, 2004; Snyder
et al. 2004). Notably, this degree of prediction is consistent with
the previous work by Thomas et al., 2012, which demonstrated
relatively poor prediction by models using ToxCast phase I in vitro
assay results (balanced accuracies ranging from approximately
0.475 to 0.55) for in vivo cancer related endpoints (endpoints
classiﬁed in ToxRef DB as mouse liver preneoplasia, mouse liver
neoplasia, mouse tumorigen, mouse liver tumors, rat tumorigen,
rat liver preneoplasia, rat liver tumors, rat thyroid tumors).
The generalizability of these results to other data sets (e.g.,
outside the EPA-OPP data sets used in the RCCPM and this study)
remains unknown, and the probable error rates for applications of
the procedure to new chemicals have not been characterized. For
developing models to predict human cancer hazard from HTS data
and data extracted from ToxRefDB, or other similar databases of
chemically-induced rodent histopathological responses, we posit
that the overall weight of evidence determinations for human risks
are key, and assay-endpoint combinations should not include ro-
dent pathologies known to be of little or no relevance to humans.
We do not interpret these limitations as undermining the program
of research described by Kleinstreuer et al. (2013), but as showing
the need to rigorously document, thoroughly evaluate and compare
the results and predictive performance of these models to results of
previous approaches, across a wide range of chemicals.
There have been a number of other qualitative exercises recently
focused on utilizing mechanistic characteristics of known carcino-
gens (e.g., Smith et al., 2015) to organize data and apply it for use in
informing potential carcinogenic hazards of chemicals. However, as
discussed and shown here, this type of prediction modeling
generally falls short. As discussed in Cox et al. (2014) and Patlewicz
et al. (2015), it is important to understand, and explicitly document,
assay performance and model performance in order to justify and
provide scientiﬁc support for employing mechanistic data for
speciﬁc uses in decision making. An indication of activity in a
mechanistic assay, including HTS, cannot be taken at face value as
proof of operation of a mechanism in the causal chain of key events
leading to any adverse outcome, including cancer. When inter-
preting mechanistic assays and HTS results, it is important to
distinguish between substances that cause activity through selec-
tive interactions (e.g., receptor-mediated responses) and those that
lead to responses through non-selective interactions that can arise
at high, often unrealistic, exposure levels, such as cytotoxicity and
non-speciﬁc assay interference (Thomas et al., 2013; Judson et al.
2015). Furthermore, for understanding and predicting human
health hazards and risks at environmentally relevant exposure
levels, it's critical to integrate knowledge of toxicocokinetics with
toxicodynamics to account for cellular response thresholds (Zhang
et al., 2014) and dose-dependent transitions (Slikker et al., 2004).
To this end, by explicitly documenting Key Events and Key Event
Relationships and employing evolved Hill considerations to char-
acterize scientiﬁc certainty/uncertainty, use of the evolved Mode of
Action Human Relevance Framework (Meek et al., 2014) or the AOP
framework (Becker et al., 2015; Villeneuve et al., 2014a,b) along
with modeling of doseeresponse for key events (Simon et al., 2014)provides a more scientiﬁcally thorough, objective and transparent
approach for integrating mechanistic information into chemical
hazard and risk evaluations compared to approaches based only on
describing characteristics in mechanistic assays.
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